Learn More
*Writing committee members are required to recuse themselves from voting on sections where their specific relationship with industry and other entities may apply; see Appendix 1 for recusal information. and select the " Policies and Development " link. Preamble The medical profession should play a central role in evaluating the evidence related to drugs,(More)
The findings and conclusions in this report are those of the Summit Participants and do not necessarily reflect the official position of the American College of Cardiology Foundation and American Heart Association. Background The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly engaged in the development(More)
BACKGROUND The leading cause of death in patients hospitalized for acute myocardial infarction is cardiogenic shock. We conducted a randomized trial to evaluate early revascularization in patients with cardiogenic shock. METHODS Patients with shock due to left ventricular failure complicating myocardial infarction were randomly assigned to emergency(More)
CONTEXT Cardiogenic shock (CS) is the leading cause of death for patients hospitalized with acute myocardial infarction (AMI). OBJECTIVE To assess the effect of early revascularization (ERV) on 1-year survival for patients with AMI complicated by CS. DESIGN The SHOCK (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) Trial,(More)
AIMS Despite the known benefits of regular exercise, the reasons why many coronary heart disease (CHD) patients engage in little physical activity are not well understood. This study identifies factors associated with low activity levels in individuals with chronic CHD participating in the STABILITY study, a global clinical outcomes trial evaluating the(More)
*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for recusal information. SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart(More)
BACKGROUND A multinational, randomized, placebo-controlled trial (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy, PURSUIT) demonstrated that the platelet glycoprotein IIb/IIIa receptor antagonist eptifibatide reduced the incidence of death or myocardial infarction among patients with acute ischemic syndromes(More)
BACKGROUND Larger infarct size measured by creatine kinase (CK)-MB release is associated with higher mortality and has been used as an important surrogate endpoint in the evaluation of new treatments for ST-segment elevation myocardial infarction (STEMI). Traditional approaches to quantify infarct size include the observed CK-MB peak and calculated CK-MB(More)